ARTICLE | Company News
GlaxoSmithKline sales and marketing update
February 2, 2015 8:00 AM UTC
Incruse is a once-daily long-acting muscarinic antagonist (LAMA) delivered via the Ellipta inhaler. Incruse comes in a seven-dose supply of 62.5 µg/actuation with a WAC of $63.01 and a 30-dose supply ...